---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-24-000028"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T20:47:27.089506+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M

## Summary
- Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.
- Nucleic Acid Production revenue $58.8M in Q4, down 69% YoY; COVID CleanCap revenue fell $105M YoY.
- Full year 2023 revenue $288.9M (down 67% YoY); net loss $138.4M vs net income $490.7M.
- Introduced 2024 revenue guidance of $265M-$285M, below 2023 actual.
- Announced CleanCap patent awards in China/Canada, supply deal with FUJIFILM Toyama Chemical, and Cygnus-Dyadic partnership.

## SEC filing metadata
- accession: 0001823239-24-000028
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/mrvi-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-24-000028
- JSON: https://secwatch.observer/filing/0001823239-24-000028.json
- Plain text: https://secwatch.observer/filing/0001823239-24-000028.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported Fourth Quarter 2023 results: revenue Quarterly revenue of $74.1 million, net income Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets.
  - Period: Fourth Quarter 2023
  - Revenue: Quarterly revenue of $74.1 million
  - Net income: Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets
  - Result: reported results
  source text: Quarterly revenue of $74.1 million, Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets, and Adjusted EBITDA margin of 28%;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported financial results for for the fourth quarter ended December 31, 2023.
  - Period: for the fourth quarter ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the fourth quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2024 results: revenue $265.0 million to $285.0 million. Guidance initiated.
  - Period: Full Year 2024
  - Revenue: $265.0 million to $285.0 million
  - Guidance: initiated
  - Result: guidance update
  source text: Introduced full year 2024 revenue guidance range of $265.0 million to $285.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2023 results: revenue Annual revenue of $288.9 million, net income Net loss of $(138.4) million.
  - Period: Full Year 2023
  - Revenue: Annual revenue of $288.9 million
  - Net income: Net loss of $(138.4) million
  - Result: reported results
  source text: Annual revenue of $288.9 million, Net loss of $(138.4) million, and Adjusted EBITDA margin of 23%;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.